EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

Tzu-Fei Wang iD, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M Sood

Cancer · 2026

DOI: 10.1002/cncr.70266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Tzu-Fei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Thrombosis, Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacokinetic studies suggest that specific prostate cancer therapies may alter the metabolism of direct oral anticoagulants (DOACs), leading to elevated risks of thrombosis or bleeding.

Methods

To assess the risk of thrombosis or bleeding, population‐based, retrospective, parallel analyses were conducted in Ontario and Alberta, Canada, among adults patients with prostate cancer who were prescribed a DOAC and a potentially interacting androgen receptor pathway inhibitor (including enzalutamide, apalutamide, or abiraterone) compared with non‐DOACs between 2012 and 2023. Analyses were stratified based on a DOAC‐inducer cohort (enzalutamide or apalutamide, which might increase the risk of thrombosis) and a DOAC‐inhibitor cohort (abiraterone, which might increase the risk of bleeding). Overlap weighted Cox proportional hazard models accounting for 37 covariates were performed independently in each jurisdiction and were pooled using random‐effects meta‐analysis.

Results

In total, 2997 individuals were included (2107 from Ontario and 890 from Alberta). In patients who received enzalutamide or apalutamide, there was no increased risk of all thrombosis in the DOAC groups compared with the non‐DOAC groups (pooled hazard ratio, 0.83; 95% confidence interval, 0.36–1.93). In patients who received abiraterone, no significant differences were observed in any bleeding events comparing the DOAC and non‐DOAC groups (pooled hazard ratio, 1.16; 95% confidence interval, 0.10–13.99). The results were consistent in multiple sensitivity analyses.

Conclusions

The concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs did not contribute to clinically meaningful changes in the risk of thrombosis or bleeding in individuals with prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsThrombosisHemorrhageAnticoagulantsAntineoplastic AgentsHumansMaleAgedRetrospective StudiesBenzamidesNitrilesOntarioPhenylthiohydantoinThiohydantoinsMiddle AgedDrug InteractionsAndrostenesAlbertaRisk Factors

Stichwörter der Autor:innen

androgen receptorsanticoagulantsdrug interactionshemorrhageprostatic neoplasmsthrombosis

Substanzen

AnticoagulantsBenzamidesNitrilesenzalutamideapalutamidePhenylthiohydantoinThiohydantoinsabirateroneAndrostenesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • ICES, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Alberta Health Services, Provincial Research and Data Services, University of Calgary, Calgary, Alberta, Canada.
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Division of Nephrology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Tzu-Fei Wang

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Wang, T. F., Clarke, A., Rath, M., Yoo, S., Fremont, D., Wu, C., Ravani, P., Bossé, D., Talarico, R., Carrier, M., & Sood, M. M. (2026). Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. Cancer. https://doi.org/10.1002/cncr.70266

Vancouver

Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C, et al. Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. Cancer. 2026. doi:10.1002/cncr.70266

BibTeX
@article{Wang2026,
  author = {Wang, Tzu-Fei and Clarke, Anna and Rath, Mitchell and Yoo, Samantha and Fremont, Deena and Wu, Cynthia and Ravani, Pietro and Bossé, Dominick and Talarico, Robert and Carrier, Marc and Sood, Manish M},
  title = {Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70266}
}
Kostenlos starten →